Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands

被引：38
|
作者：
van der Kooij, M. K. [1 ]
Joosse, A. [1 ]
Speetjens, F. M. [1 ]
Hospers, G. A. P. [2 ]
Bisschop, C. [2 ]
de Groot, J. W. B. [3 ]
Koornstra, R. [4 ]
Blank, C. U. [5 ]
Kapiteijn, E. [1 ]
机构：
[1] Leiden Univ, Med Ctr, Dept Clin Oncol, POB 9600, NL-2300 RC Leiden, Netherlands
[2] Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands
[3] Isala, Dept Med Oncol, Zwolle, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, Nijmegen, Netherlands
[5] Netherlands Canc Inst NKI AVL, Dept Med Oncol, Amsterdam, Netherlands
来源：
ACTA ONCOLOGICA | 2017年 / 56卷 / 01期
关键词：
IPILIMUMAB; TRIAL;
D O I：
10.1080/0284186X.2016.1260773
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：101 / 103
页数：3
相关论文
共 50 条
  • [1] Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma
    Simeone, Ester
    Grimaldi, Antonio M.
    Ascierto, Paolo A.
    [J]. MELANOMA MANAGEMENT, 2015, 2 (01) : 41 - 50
  • [2] Activity of anti-PD1 drugs in uveal melanoma patients.
    Piperno-Neumann, Sophie
    Servois, Vincent
    Mariani, Pascale
    Cassoux, Nathalie
    Barnhill, Raymond
    Rodrigues, Manuel Jorge
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?
    Bender, Carolin
    Enk, Alexander
    Gutzmer, Ralf
    Hassel, Jessica C.
    [J]. CANCER MEDICINE, 2017, 6 (07): : 1581 - 1586
  • [4] Predicting the response to anti-PD1 therapy in metastatic melanoma
    Heinzerling, Lucie
    Kirchberger, Michael Constantin
    Walter, Lisa
    Schuler, Gerold
    [J]. TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S576 - S579
  • [5] Intralesional anti-PD1 treatment in patients with metastatic melanoma: The pilot study.
    Samoylenko, Igor
    Korotkova, Olga V.
    Zabotina, Tatiana
    Demidov, Lev V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [6] Anti-PD1 role in treatment of cutaneous melanoma
    Mateus, Christine
    Libenciuc, Cristina
    Robert, Caroline
    [J]. BULLETIN DU CANCER, 2016, 103 (06) : S4 - S11
  • [7] PERFORMANCE STATUS AS A PREDICTOR OF RESPONSE TO ANTI-PD1 FOR METASTATIC MELANOMA
    Wong, A.
    Williams, M.
    Milne, D.
    Morris, K.
    Lau, P.
    Spruyt, O.
    Fullerton, S.
    McArthur, G.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 71 - 71
  • [8] Metastatic site and response to pembrolizumab (anti-PD1 antibody) in melanoma
    Tumeh, Paul Camille
    Rosenblum, Michael
    Handley, Nathan
    Tsai, Katy
    Rodriguez, Robert S. Rodriguez
    Khurana, Niharika
    Harview, Christina
    Spasic, Marko
    Sanchez, Phillip J.
    Chang, Jeremy
    Shintaku, I. Peter
    Taylor, Emma
    Chmielowski, Bartosz
    Grogan, Tristan
    Elashoff, David A.
    Pierce, Robert H.
    Daud, Adil
    [J]. CANCER RESEARCH, 2015, 75
  • [9] Purple papules during anti-PD1 immunotherapy for metastatic melanoma
    De Luca, Erika V.
    Catapano, Silvia
    Del Regno, Laura
    Di Stefani, Alessandro
    Peris, Ketty
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 (04): : 630 - 632
  • [10] Toxicity and Survival for Metastatic Melanoma Patients Treated With Anti-PD1 Therapy and Radiation Treatment
    Mowery, Y. M.
    Patel, K.
    Olson, A. C.
    Khan, M. K.
    Salama, J. K.
    Salama, A. K.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S158 - S159
12345